Lonopin® (Enoxaparin) — Low Molecular Weight Heparin for DVT Prevention and Treatment

The Most Widely Used Low Molecular Weight Heparin for Anticoagulation in Clinical Practice

Lonopin® (Enoxaparin) is a low molecular weight heparin (LMWH) used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes. It works by inhibiting Factor Xa and thrombin — key enzymes in the coagulation cascade — preventing blood clot formation and extension. Lonopin is available in multiple strengths and delivery formats to cover the full range of anticoagulation indications from prophylaxis to treatment.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Lonopin (Enoxaparin) in all available strengths — 20mg, 40mg, 60mg, 80mg, and 100mg prefilled syringes and the Lonopin Pen — to hospitals, surgical centres, cardiology units, and pharmacies across India. Manufactured by leading pharmaceutical companies, Lonopin is one of the most important anticoagulant medicines in modern clinical practice.

What is Lonopin (Enoxaparin)?

Lonopin contains Enoxaparin sodium — a low molecular weight heparin derived from porcine intestinal mucosa heparin through controlled depolymerisation. With an average molecular weight of approximately 4,500 Daltons, Enoxaparin has a more predictable anticoagulant response than unfractionated heparin and does not require routine laboratory monitoring in most clinical situations.

Enoxaparin exerts its anticoagulant effect primarily through anti-Factor Xa activity — inhibiting the conversion of prothrombin to thrombin and preventing fibrin clot formation. Unlike unfractionated heparin, Enoxaparin has higher anti-Xa to anti-IIa ratio, providing more selective anticoagulation with a more predictable dose-response relationship.

Full prescribing information is available at the FDA label for Enoxaparin.

Clinical Studies and Evidence

MEDENOX Trial (Enoxaparin for Medical Patients) Published in the New England Journal of Medicine (1999), the MEDENOX trial demonstrated that Enoxaparin 40mg once daily significantly reduced the incidence of venous thromboembolism (VTE) in acutely ill medical patients — reducing VTE from 14.9% to 5.5% compared to placebo — establishing Enoxaparin as the standard of care for medical VTE prophylaxis.

ESSENCE Trial (Enoxaparin in Unstable Angina/NSTEMI) Published in the New England Journal of Medicine (1997), the ESSENCE trial demonstrated Enoxaparin was superior to unfractionated heparin in reducing the composite endpoint of death, myocardial infarction, and recurrent angina in patients with unstable angina and NSTEMI.

SYNERGY Trial (Enoxaparin vs UFH in High-Risk NSTEMI) The SYNERGY trial confirmed Enoxaparin’s non-inferiority to unfractionated heparin in high-risk NSTEMI patients undergoing early invasive strategy — further establishing its role in acute coronary syndrome management.

Surgical Prophylaxis Studies Multiple large randomised trials across orthopaedic surgery (hip and knee replacement), abdominal surgery, and oncological surgery demonstrate Enoxaparin significantly reduces DVT and PE rates compared to placebo and is at least as effective as unfractionated heparin with improved convenience.

Available Strengths

Lonopin is available in the following strengths:

Indications — What Lonopin is Used For

DVT Prophylaxis:

• Prevention of DVT in patients undergoing hip replacement surgery
• Prevention of DVT in patients undergoing knee replacement surgery
• Prevention of DVT in patients undergoing abdominal surgery
• Prevention of VTE in acutely ill medical patients with restricted mobility
• Prevention of DVT in oncology patients at risk of VTE

DVT and PE Treatment:

• Treatment of acute DVT — with or without PE
• Inpatient and outpatient treatment of DVT
• Bridge therapy during warfarin initiation

Acute Coronary Syndromes:

• Treatment of unstable angina and NSTEMI — in combination with aspirin
• Treatment of STEMI — in conjunction with thrombolysis or PCI

Other:

• Anticoagulation in haemodialysis and haemofiltration circuits
• Prevention of clotting in extracorporeal circulation

For detailed indication information refer to MedlinePlus Enoxaparin.

Key Benefits of Lonopin

Predictable Anticoagulant Response Enoxaparin’s predictable dose-response relationship allows weight-based dosing without routine anti-Xa monitoring in most patients — simplifying clinical management compared to unfractionated heparin.

No Routine Laboratory Monitoring Required Unlike unfractionated heparin requiring frequent aPTT monitoring, Enoxaparin does not require routine coagulation monitoring in standard clinical practice — reducing laboratory burden and enabling outpatient treatment.

Outpatient DVT Treatment Enoxaparin enables outpatient treatment of uncomplicated DVT — avoiding hospitalisation and reducing healthcare costs while maintaining equivalent efficacy to inpatient treatment.

Lower Risk of Heparin-Induced Thrombocytopenia Enoxaparin has a significantly lower risk of heparin-induced thrombocytopenia (HIT) compared to unfractionated heparin — an important safety advantage particularly in surgical patients.

Once or Twice Daily Dosing Prophylactic dosing is once daily — simplifying administration compared to unfractionated heparin requiring continuous infusion or multiple daily injections.

Convenient Prefilled Syringes Ready-to-use prefilled syringes and the Lonopin Pen enable accurate dose delivery with minimal preparation — improving safety and ease of administration.

How Lonopin Works

The coagulation cascade involves a series of enzyme activations that ultimately lead to thrombin generation and fibrin clot formation. Key steps include:

• Factor Xa converts prothrombin to thrombin (Factor IIa)
• Thrombin converts fibrinogen to fibrin — forming the clot scaffold
• Thrombin also activates platelets and amplifies the coagulation cascade

Lonopin works by:

• Binding to antithrombin (AT) — a naturally occurring coagulation inhibitor
• Accelerating AT’s inhibitory activity approximately 1,000-fold
• Anti-Factor Xa activity — prevents conversion of prothrombin to thrombin (primary mechanism)
• Anti-Factor IIa (antithrombin) activity — directly inhibits thrombin (secondary mechanism)
• Anti-Xa:anti-IIa ratio of approximately 3.8:1 — more selective for Xa inhibition than UFH
• Net effect — preventing clot formation and extension without lysing existing clots

For a detailed mechanism overview refer to the American Society of Hematology anticoagulation guidelines.

Lonopin Dosing Guide — All Indications

Special Populations:

• Renal impairment (CrCl <30 mL/min): Prophylaxis 20mg once daily; Treatment 1mg/kg once daily
• Elderly (>75 years, STEMI): No IV bolus — 0.75mg/kg SC every 12 hours
• Obesity: Use actual body weight for treatment dosing — maximum 180mg per dose

Full dosing guidelines available at Drugs.com Enoxaparin Dosage.

Lonopin Pen — Multidose Delivery Device

The Lonopin Pen is a multidose injection device designed for patients requiring outpatient Enoxaparin therapy:

• Delivers accurate, reproducible doses
• Adjustable dose dial for weight-based dosing
• Reduces needle phobia — hidden needle design
• Suitable for self-injection in outpatient DVT treatment
• Particularly useful for patients on extended anticoagulation therapy
• Reduces waste compared to multiple single-dose prefilled syringes

Anti-Xa Monitoring — When is it Required?

Routine anti-Xa monitoring is not required for most patients. However monitoring is recommended in:

• Renal impairment (CrCl <30 mL/min)
• Extremes of body weight (very low <45kg or very high >100kg)
• Pregnancy — dosing requirements change throughout pregnancy
• Prolonged therapy in oncology patients
• Patients at high risk of bleeding

Target anti-Xa levels:

• Prophylaxis: 0.2-0.4 IU/mL (4 hours post-dose)
• Treatment (twice daily): 0.6-1.0 IU/mL (4 hours post-dose)
• Treatment (once daily): 1.0-2.0 IU/mL (4 hours post-dose)

Who Should Use Lonopin

Lonopin is prescribed for:

• Surgical patients at risk of DVT — orthopaedic, abdominal, oncological surgery
• Acutely ill medical patients with restricted mobility
• Patients with acute DVT or PE requiring treatment
• Patients with unstable angina or NSTEMI
• Patients requiring bridge anticoagulation during warfarin initiation
• Cancer patients at increased VTE risk

Lonopin is prescribed by surgeons, cardiologists, physicians, haematologists, and general practitioners. A.K. Pharma supplies Lonopin in all strengths to hospitals, surgical centres, cardiology units, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include injection site haematoma, bruising, mild thrombocytopenia, and elevated liver enzymes.

Serious side effects include:

• Haemorrhage — major bleeding including intracranial, retroperitoneal, and GI bleeding
• Heparin-induced thrombocytopenia (HIT) — rare but serious — monitor platelet count
• Spinal/epidural haematoma — risk increased with neuraxial anaesthesia or spinal puncture
• Hyperkalaemia — particularly in patients with renal impairment or diabetes
• Hypersensitivity reactions

Full side effect information available at FDA Enoxaparin Safety Information.

Precautions

• Monitor platelet count regularly — discontinue if HIT suspected
• Withhold before neuraxial anaesthesia — timing depends on dose and renal function
• Reduce dose in renal impairment (CrCl <30 mL/min)
• Use with caution in patients with active bleeding or high bleeding risk
• Monitor for signs of bleeding — particularly in elderly and low body weight patients
• Enoxaparin is not interchangeable unit-for-unit with other LMWH preparations
• Reversal agent: Protamine sulphate partially reverses Enoxaparin (neutralises anti-IIa activity, partial anti-Xa reversal)
• Andexanet alfa provides complete Factor Xa reversal if available

Storage and Handling

• Store at room temperature below 25°C
• Do not freeze prefilled syringes or pen
• Keep out of reach of children
• Single-use prefilled syringes — discard after use
• Lonopin Pen — multidose device, follow manufacturer instructions for storage and use

As a responsible medicine distributor in Delhi, A.K. Pharma stores all Lonopin strengths under manufacturer-recommended conditions ensuring product integrity for every supply.

Manufacturer Information

Lonopin (Enoxaparin) is manufactured by leading Indian and international pharmaceutical companies. The originator Enoxaparin (Clexane/Lovenox) was developed by Sanofi and has been available for over 30 years. Generic Enoxaparin preparations including Lonopin are approved by regulatory authorities and provide equivalent anticoagulant activity. A.K. Pharma supplies only genuine Lonopin sourced from authorized distributors.

Related Blood and Anti-Coagulant Medicines Available at A.K. Pharma

• Anagrelide — platelet-reducing agent for essential thrombocythaemia
• Browse all Blood Medicines available at A.K. Pharma
• Browse all Anti Coagulant Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Lonopin used for? Lonopin (Enoxaparin) is used for prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes. More information available at MedlinePlus.

Q. What is the generic name of Lonopin? The generic name of Lonopin is Enoxaparin sodium. It belongs to the low molecular weight heparin (LMWH) class of anticoagulant medicines.

Q. What is the difference between Lonopin 20mg, 40mg, and 60mg? Lonopin 20mg is used for DVT prophylaxis in low-risk surgical patients and in renal impairment. Lonopin 40mg is the standard prophylactic dose for medical and surgical patients. Lonopin 60mg and higher doses are used for treatment of established DVT/PE — dosed at 1mg/kg twice daily based on body weight.

Q. Does Lonopin require blood test monitoring? Routine anti-Xa monitoring is not required for most patients. Monitoring is recommended in renal impairment, extremes of body weight, pregnancy, and other special populations.

Q. What is the Lonopin Pen? The Lonopin Pen is a multidose injection device for accurate and convenient subcutaneous Enoxaparin delivery — particularly useful for patients on outpatient treatment requiring daily self-injection.

Q. Is Lonopin available in India? Lonopin is available across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for all strengths and bulk supply.

Q. What is the price of Lonopin in India? Lonopin price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Lonopin from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Lonopin in bulk? Yes. A.K. Pharma supplies all Lonopin strengths in bulk to hospitals, surgical centres, cardiology units, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Lonopin from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Lonopin sourced from authorized distributors
• All strengths available — 20mg, 40mg, 60mg, 80mg, 100mg and Pen
• Bulk supply available for hospitals and surgical centres
• Prompt response to all quote requests
• Serving surgeons, cardiologists, and physicians across Delhi NCR and India

Contact A.K. Pharma for Lonopin Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in